IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer

Preclinical studies indicate that activated IGF‐1R can drive endocrine resistance in ER‐positive (ER+) breast cancer, but its clinical relevance is unknown. We studied the effect of IGF‐1R signaling on tamoxifen benefit in patients and we searched for approaches to overcome IGF‐1R‐mediated tamoxifen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruger, Dinja T., Alexi, Xanthippi, Opdam, Mark, Schuurman, Karianne, Voorwerk, Leonie, Sanders, Joyce, van der Noort, Vincent, Boven, Epie, Zwart, Wilbert, Linn, Sabine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065127/
https://www.ncbi.nlm.nih.gov/pubmed/31490549
http://dx.doi.org/10.1002/ijc.32668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065127/
https://www.ncbi.nlm.nih.gov/pubmed/31490549
http://dx.doi.org/10.1002/ijc.32668

Ejemplares similares